I am interested in utilizing different mouse models, including genetically engineered mouse model (GEMM), allograft model (subcutaneously and orthotopically) and patient-derived xenograft to look for novel treatment strategies for oncogene-driven non-small cell lung cancer (NSCLC), such as EGFR, HER2, KRAS and so on.

Dr. Shuai Li is an instructor at New York University School of Medicine. He received MD and PhD from Medical School of Tongji University. After oncology training at Shanghai Pulmonary Hospital, he joined Dana-Farber Cancer Institute as a research fellow in Dr. Kwok-kin Wong’s lab. He is a translational lung cancer investigator who focus on understanding the genetic alterations driving lung tumor formation and the testing of new targeted and immune lung cancer therapies. He established novel KRAS-G12C, EGFR-exon20 and HER2-exon20 mouse models and directed “mouse clinical trials” to help uncover the molecular mechanisms and genetic underpinnings of sensitivity and resistance to targeted therapies and immunotherapy. He has extensive experience in grant applications, publications in top-tier journals (e.g. first and co-first authors in Cancer Discovery, Journal of Experimental Medicine, Clinical Cancer Research, Cancer Research, Cell reports, lung cancer), conference presentations, and peer review.